That is a tough question to have a simple answer to.
We have a complex market in Canada for pharmaceuticals, what with the provincial and federal responsibilities for regulation. The provinces and territories are responsible for the public drug plan, and there are commercial pharmacies as well as free-market pharmacies. To have one system that looks after the management of all of those key players would be very challenging.
Certainly some of the policies we've seen implemented over the last number of years regarding generic pricing have probably played a role. Some business decisions by manufacturers have come into play. They have at times wondered whether there was any value in continuing to make a certain product. There have been decisions from some of the brand name companies on whether they would make a product in a generic version. These decisions would probably be made globally, as opposed to in Canada, so it's all very challenging.
I think there probably are some balances we need to strike in our pricing policies as well as on the supply-and-demand side of it.